Evaluating Long-Acting and Oral HIV Prevention Choices Integrated with Community Sexual and Reproductive Health Services in Rural South Africa for Ages 15 to 30
Led by Africa Health Research Institute · Updated on 2026-07-09
2052
Participants Needed
1
Research Sites
22 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effectiveness and real-world use of offering a choice of HIV Pre-Exposure Prophylaxis PrEP options through community-based sexual and reproductive health SRH services for adolescents and young adults aged 15 to 30 living in rural South Africa. This trial compares adding long-acting PrEP options like injectable cabotegravir CAB LA and dapivirine vaginal ring, along with post-exposure prophylaxis PEP, to the current standard daily oral PrEP in community settings. The study aims to improve PrEP uptake, retention, and reduce sexually transmissible HIV in this population.
Participants in intervention clusters are offered a choice between daily oral tenofoviremtricitabine, injectable CAB LA given every two months, dapivirine vaginal rings changed every three months, or PEP packs. The control clusters receive the standard oral PrEP with integrated community SRH services. Follow-up includes HIV and pregnancy testing, STI management, and peer navigator support to promote adherence. Safety monitoring involves blood tests for liver and kidney function, with visits spaced from monthly to every few months depending on the PrEP method.
During the study, participants will have regular assessments including HIV testing every two months, pregnancy testing, STI screening, and blood tests annually. Peer navigators provide psychosocial support and reminders for follow-up visits. Researchers will track PrEP uptake, retention, adherence, HIV incidence, and safety outcomes over 14 months. The study also explores the acceptability, feasibility, and cost-effectiveness of delivering these PrEP options through community-based services. Total study duration extends up to 20 months for some outcome measures.
CONDITIONS
Brief Title
Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT
Research Team
M
Maryam G Shahmanesh, MBBChir PhD
L
Limakatso Lebina, MBBS PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Young men and women aged 15 to 30 living in the 40 study clusters and attending integrated sexual and reproductive health services
Documented HIV negative test
Suitable for PrEP and/or already using PrEP
Weight greater than 35 kilograms
Understand the dosing schedule and HIV testing requirements
Willing to share details with a peer navigator to support follow-up
If pregnant, breastfeeding, or planning pregnancy, may be offered CAB LA if HIV risk outweighs unknown safety risks, with oral PrEP as a safe alternative
You will not qualify if you...
History or presence of allergy to study drugs or their components
Investigator assessment of unsuitability
For CAB LA: taking contraindicated medications (e.g., Carbamazepine, Rifampin), severe mental health disorder, untreated hepatitis B or C, or abnormal liver function tests
For Dapiring: pregnancy
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Up to 20 months
Participants receive tailored peer-led support and are offered either daily oral PrEP or a choice of long-acting injectable cabotegravir, dapivirine vaginal ring, or post-exposure prophylaxis in the intervention clusters. Control clusters receive standard daily oral PrEP with community-based sexual and reproductive health services. Follow-up includes HIV and pregnancy testing, STI management, and adherence support.
Regular visits every 1 to 3 months depending on treatment choice
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Continued Access Study Providing Ongoing HIV Treatment for Participants from ViiV Healthcare Parent Studies
Long-Term Follow-Up Study of HIV-Infected Individuals from HIV-NAT Trials to Evaluate Clinical Outcomes and Treatment Effects
Phase 2b Study Comparing Oral VH4524184 with Standard HIV Treatment in Adults Newly Diagnosed with HIV-1
Evaluating Treatment Strategies for Managing Virologic Failure on Tenofovir, Lamivudine, and Dolutegravir TLD in People with HIV in Sub-Saharan Africa
Pilot Study of a Peer-Driven Injection Setting Intervention to Prevent HIV, Hepatitis C, and Overdose Among People Who Inject Drugs in Baltimore
Phase 1 Study of VH4011499 Safety, Tolerability, and Pharmacokinetics
with Single and Multiple Doses in Adults Without HIV
Safety and Effectiveness of JL18008 Injections Added to Standard HIV Therapy
in Adults with HIV Who Have Low Immune Response
A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Phase 12 Study to Assess Safety and Effects of Cabotegravir in Newborns Exposed to HIV-1
Phase III Study Comparing Cabotegravir and Rilpivirine Ultra Long-Acting or Long-Acting Treatments in Adolescents and Adults With Suppressed HIV
Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of Single-Dose VH4367310 in Healthy Adults Aged 18 to 55 Years
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Long-acting HIV pre-exposure prophylaxis integrated with community-based sexual and reproductive health services in South Africa (LAPIS): study protocol for a hybrid (1a) cluster randomised controlled phase 3B trial of effectiveness and implementation.
Jacob Busang, Thembelihle Zuma, Natsayi Chimbindi...